Financial stocks were mostly lower, with the NYSE Financial Sector Index falling 0.6% and the S&P Financial 100 Index dropping about 0.6%.
On Friday, Shares of Genworth Financial, Inc. (NYSE:GNW), gained 1.02% to $7.94. The company exchanged hands with 25,808,252 shares as compared to its average daily volume of 7,777,860 shares. The company has the market capitalization of 3.95B.
Genworth Financial, Inc. provides insurance, retirement, and homeownership solutions in the United States and internationally. It operates through U.S. Life Insurance, International Mortgage Insurance, U.S. Mortgage Insurance, International Protection, and Runoff segments.
On Friday, Technology stocks were moderately lower, with shares of technology companies in the S&P 500 declining about 0.4% in afternoon trade.
Among Technology stocks, Shares of Micron Technology, Inc. (NASDAQ:MU), declined -1.24% to $27.93, during its last trading session. The company exchanged hands with 18,451,268 shares as compared to its average daily volume of 22,391,700 shares. The company has the market capitalization of 30.09B.
Micron Technology, Inc., together with its auxiliaries, provides semiconductor solutions worldwide. The company manufactures and markets dynamic random access memory (DRAM), NAND flash, and NOR flash memory products; and packaging solutions and semiconductor systems.
At the end of Friday’s trade, Shares of Oncothyreon Inc (NASDAQ:ONTY), gained 0.88% to $3.42.
Oncothyreon, declared the presentation of positive data from the company’s ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor for the treatment of breast cancer, at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. The first presentation updated data from the Phase 1b trial of ONT-380 in combination with Xeloda(R) (capecitabine)and Herceptin(R) (trastuzumab) in third line treatment of HER2-positive metastatic breast cancer. The data support Oncothyreon’s plans to initiate a blinded, randomized, placebo-controlled Phase 2 trial in this indication. The second presentation focused on the role of ONT-380 in the treatment of HER2-positive breast cancer central nervous system (CNS) metastases.
The Phase 1b trial (ClinicalTrials.gov Identifier NCT02025192) of ONT-380 in combination with Xeloda(R) (capecitabine) and/or Herceptin(R) (trastuzumab) is a parallel dose escalation study in patients formerly treated with Herceptin and Kadcyla(R) (ado-trastuzumab emtansine or TDM-1) for metastatic breast cancer. Data were presented for 32 patients, counting seven in the ONT-380 plus Xeloda cohort, 13 in the ONT-380 plus Herceptin cohort and 12 in the ONT-380 plus Xeloda and Herceptin cohort. Twenty-seven of the patients were evaluable for best overall response using RECIST 1.1 criteria. Considering the three cohorts together, a complete response (CR) was seen in two patients, a partial response (PR) in 12 patients, stable disease (SD) in nine patients and progressive disease (PD) in four patients.
Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates comprise ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, counting breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, in addition to certain types of lung cancer.
Finally, United States Steel Corp. (NYSE:X), ended its last trade with -0.08% decline, and closed at $24.40.
On May 13, United States Steel Corp., President and Chief Executive Officer Mario Longhi declared that Nancy Sykes has been named vice president - human resources. In this position, she will be responsible for all facets of the company’s human resources, in addition to medical and health services. Sykes will be based at the company’s Pittsburgh headquarters and will join the company’s executive administration team.
Sykes earned a bachelor’s degree in mechanical engineering from the Rochester Institute of Technology.
United States Steel Corporation produces and sells flat-rolled and tubular steel products in North America and Europe. It operates through three segments: Flat-Rolled Products (Flat-Rolled), U. S. Steel Europe (USSE), and Tubular Products (Tubular). The Flat-Rolled segment offers slabs, rounds, strip mill plates, sheets, and tin mill products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
